Satellos Bioscience Inc.
TSX: MSCL.TO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Toronto Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Francis Gleeson
- Employees
- 14
- Headquarters
- Toronto, Canada
- IPO year
- 2008
- Market cap
- CA$158.6M
- Website
- https://satellos.com
Loading MSCL…
Loading profile data…Frequently asked questions about MSCL
What does Satellos Bioscience Inc. (MSCL.TO) do?
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery...
Where does MSCL.TO trade?
Satellos Bioscience Inc. (MSCL.TO) trades on the Toronto Stock Exchange.
What sector is MSCL.TO in?
Satellos Bioscience Inc. (MSCL.TO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Satellos Bioscience Inc.?
Francis Gleeson is the chief executive officer of Satellos Bioscience Inc. (MSCL.TO).
Where is Satellos Bioscience Inc. headquartered?
Satellos Bioscience Inc. is headquartered in Canada.
Does MSCL.TO pay a dividend?
Satellos Bioscience Inc. (MSCL.TO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MSCL.TO go public?
Satellos Bioscience Inc. (MSCL.TO) completed its initial public offering in 2008.